Intellia reports phase 3 HAELO trial success for lonvo-z
Intellia released positive Phase 3 data for its HAE treatment lonvo-z, received FDA guidance, and ended the quarter with strong liquidity.
View filing at SEC.gov →2 most recent filings and news items mentioning NTLA. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/NTLA/news?limit=20"
Pull NTLA filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayIntellia released positive Phase 3 data for its HAE treatment lonvo-z, received FDA guidance, and ended the quarter with strong liquidity.
View filing at SEC.gov →Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z, achieving 87% reduction in attacks versus placebo with 62% of patients attack-free. The in vivo CRISPR gene editing therapy results were published in NEJM and could support a potential regulatory su
View filing at SEC.gov →